Novartis says lung disease drug studies show positive results
Thursday, May 21, 2015
Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
The Swiss drugmaker said data demonstrated QVA149, administered twice-daily, improved lung function compared to placebo after 12 weeks of treatment, meeting its primary objective
Novartis said in studies NVA237, administered twice-daily, demonstrated significant and clinically meaningful improvements in lung function at week 12 in moderate-to-severe COPD patients compared to placebo, meeting its primary objective
reuters.com
